摘要
目的观察罗格列酮(RSG)治疗2型糖尿病(T2DM)前后血清高敏C反应蛋白(hsC-RP)的变化。方法采用随机、双盲、安慰剂平行对照法将120例已合用磺脲类和双胍类药物的T2DM患者随机分为安慰剂组和RSG组,治疗12周。结果安慰剂组的HbA1c明显下降(P<0.05),其他指标均无显著变化;RSG组与基线比较FPG、2hPG、HbA1c、胰岛素抵抗指数、hsC-RP均明显下降(P均<0.01)。结论RSG治疗T2DM,除能改善胰岛素抵抗,降低血糖,还有明显的抗炎症作用,使hsC-RP下降。
Objective To observe the change of serum high sensitivity C-reactive protein（hsCRP） in patients with type 2 diabetes after treatment with rosiglitazone. Methods A 12-week randomized, double-blind,placebo controlled study was performed to compare the effects of placebo and rosiglitazone in 120 type 2 diabetic patients who had received metformin and sulfonylureas treatment. Results A significant reduction in glycosylated hemoglobin （HbA1 c） was observed during treatment with placebo（P 〈0.05）, and other indexes varied non-significantly in placebo group. Fasting plasma glucose, postprandial plasma glucose, HbA1c, hsCRP were all reduced significantly in rosiglitazone group. Conclusions Rosiglitazone can reduce plasma glucose and hsCRP in patients with type 2 diabetes, which suggests that rosiglitazone possesses anti-inflammatory properties.
出处
《中国糖尿病杂志》
CAS
CSCD
北大核心
2008年第8期487-488,共2页
Chinese Journal of Diabetes
关键词
罗格列酮
糖尿病
2型
C反应蛋白
Rosiglitazone
Diabetes mellitus, type 2
C-reactive protein
